Abstract

YALE PATHOLOGY TISSUE SERVICES SHARED RESOURCE PROJECT SUMMARY/ABSTRACT Yale Pathology Tissue Services (YPTS) was established in 2006 to provide comprehensive tissue-related services and material for investigators at Yale Cancer Center (YCC), Yale University, and beyond. YPTS is committed to providing the maximum amount and quality of human tissue for research at Yale without impacting diagnostic quality, accuracy, and safety in anatomic pathology. YPTS provides a set of policies and standard operating procedures that provide for optimal management of pathology resources, including fresh, frozen, and fixed tissue, and as well as tissue from the Yale Pathology Departmental Archives. During the most recent funding period, 328 Principal Investigators used YPTS. Of the 328, 121 users (37%) were YCC members. The majority of the use was from Developmental Therapeutics (DT) and Genomics, Genetics and Epigenetics (GGE). There are four divisions to YPTS: Tissue Procurement and Distribution (TPD), Developmental Histology and Tissue Microarrays (DHTMA), Clinical Trials Tissue Services (CTTS), and Specialized Translational Services (STS). Together these divisions aim to: 1) provide access to tissue services, 2) maximize the access of translational investigators to human tissues, 3) prepare and submit human tissue for clinical trials around the world, and 4) specialize in quantitative analysis.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-40
Application #
9772265
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
40
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520

  Publications

Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564

Showing the most recent 10 out of 675 publications